CJC-1295 vs Ipamorelin
Both are designed to make the body release more growth hormone, by different routes, and they’re often sold together as a pre-mixed blend. Neither is approved, and both are banned in tested sport.
At a glance
The facts side by side. Tap a name for its calculator.
| CJC-1295 (no DAC) | Ipamorelin |
|---|---|
| Evidence | |
| Limited human evidence. Small, short studies only. | Limited human evidence. Small, short studies only. |
| Vial sizes | |
| 2, 5, 10 mg | 2, 5, 10 mg |
| Usual dose range | |
| 100–300 mcg | 100–300 mcg |
| How often | |
| 1–2× daily | 1–3× daily, before bed |
| Unmixed | |
| Freezer −20°C | Freezer −20°C |
| After mixing | |
| Fridge 2–8°C, use within 28 days | Fridge 2–8°C, use within 28 days |
How they work
CJC-1295 is a lab-made version of growth-hormone-releasing hormone (GHRH), the signal that tells the pituitary gland to release growth hormone. Ipamorelin acts on a different receptor, the ghrelin receptor, which also triggers release. Acting on both routes at once is the idea behind the blend; human data on the combination is limited.
Side effects
Small early studies found ipamorelin had little effect on cortisol or prolactin. Flushing, headache and tingling have been reported with CJC-1295. The long-term safety of either hasn’t been studied.
Counting a blend dose
With a 1:1 blend, a quoted dose usually means each peptide, not the total: ‘200 mcg’ means 200 mcg of CJC-1295 plus 200 mcg of ipamorelin. Reading it the other way halves or doubles the dose. The calculator works blends out per peptide and says so next to the answer.
The short version
Both are unapproved, banned in tested sport and backed by limited human data, so claims that one is better, or that combining them multiplies the effect, aren’t well supported. Low growth hormone can be tested for; if it’s a real concern, that’s a conversation for an endocrinologist.